TAE Life Sciences and OSUCCC – James Partner to Develop Boron-Based Cancer Therapies

TAE Life Sciences (TLS) and the OSUCCC – James are initiating a collaboration to develop boron-based drug compounds for cancer therapy. The two entities have signed a letter of intent, signaling their commitment to the joint project. The letter of intent formalizes the preliminary agreement between TLS, a company focused on boron-based pharmaceuticals, and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). The collaboration will focus on research and development efforts aimed at creating new cancer therapies utilizing boron compounds.

Newsflash | Powered by GeneOnline AI
Date: May 5, 2025

Related posts:

Data Clean Rooms Revolutionize Secure Healthcare Data Sharing 15-mg Dose with Corticosteroid Taper Maintains Remission Better Than Placebo from Weeks 12-52 Mice develop fibromyalgia-like pain after receiving gut microbiota from human patients Specialty Distributors Aid Pharmaceutical Launches with Patient Access Programs and Data Analytics.

Author

Mark Chiang